30 November 2020>: Clinical Research
Clinical Outcomes of 130 Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Palbociclib plus Endocrine Therapy and Subsequent Therapy: A Real-World Single-Center Retrospective Study in China
Chang Liu 12CDEF* , Ting Li 12CDEF* , Zhonghua Tao 12B , Jun Cao 12B , Leiping Wang 12B , Jian Zhang 12B , Biyun Wang 12A* , Xichun Hu 12A*DOI: 10.12659/MSM.927187
Med Sci Monit 2020; 26:e927187
Figure 4 Progression-free survival of the subsequent therapy after progression on palbociclib-based treatment. Survival curve of PFS was plotted by the Kaplan-Meier method and compared by the log-rank test. P-values of less than 0.05 indicate statistical significance. PFS – progression-free survival; ET – endocrine therapy.